At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SPRY ARS PHARMACEUTICALS INC
Pre-Mkt 08-31 07:51:46 EDT
5.89
-0.14
-2.32%
盘前5.90
+0.01+0.14%
07:00 EDT
High6.03Low5.86Vol1.19M
Open6.00D1 Closing6.03Amplitude2.90%
Mkt Cap585.74MTradable Cap282.92MTotal Shares99.45M
T/O7.04MT/O Rate2.48%Tradable Shares48.03M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ARS Pharmaceuticals Chief Commercial Officer Margaret Ekins Smith Files Initial Beneficial Ownership Statement
Reuters  ·  08-18
ARS Pharmaceuticals Chief Commercial Officer Margaret Ekins Smith Files Initial Beneficial Ownership Statement
ARS Pharmaceuticals Lawsuit Focuses on Alleged Neffy Coverage Disclosures and SPRY Stock Drop
TIPRANKS  ·  08-15
ARS Pharmaceuticals Lawsuit Focuses on Alleged Neffy Coverage Disclosures and SPRY Stock Drop
ARS Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $18 from $24
THOMSON REUTERS  ·  08-14
ARS Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $18 from $24
ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises
MT Newswires Live  ·  08-14
ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises
ARS Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-14
ARS Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
ARS Pharmaceuticals Q2 Neffy Revenue Rises as Epinephrine Market Share Doubles
Reuters  ·  08-14
ARS Pharmaceuticals Q2 Neffy Revenue Rises as Epinephrine Market Share Doubles
ARS Pharmaceuticals Q2 EPS $(0.63) Misses $(0.48) Estimate, Sales $33.658M Beat $31.321M Estimate
Benzinga Earnings  ·  08-14
ARS Pharmaceuticals Q2 EPS $(0.63) Misses $(0.48) Estimate, Sales $33.658M Beat $31.321M Estimate
ARS Pharmaceuticals Q2 EPS USD -0.63
THOMSON REUTERS  ·  08-14
ARS Pharmaceuticals Q2 EPS USD -0.63
ARS Pharmaceuticals - Realigns Commercial Investment; Expects Cash Flow Breakeven by End of 2027
THOMSON REUTERS  ·  08-14
ARS Pharmaceuticals - Realigns Commercial Investment; Expects Cash Flow Breakeven by End of 2027
Press Release: ARS Pharmaceuticals Outlines Strategic Priorities, Including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
Dow Jones  ·  08-14
Press Release: ARS Pharmaceuticals Outlines Strategic Priorities, Including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
ARS Pharmaceuticals Lawsuit Alleges Investors Were Misled Before SPRY Stock Drop
TIPRANKS  ·  08-08
ARS Pharmaceuticals Lawsuit Alleges Investors Were Misled Before SPRY Stock Drop
ARS Pharmaceuticals Schedules Conference Call to Report Q2 2026 Results
Reuters  ·  08-03
ARS Pharmaceuticals Schedules Conference Call to Report Q2 2026 Results
ARS Pharma Names President Donn Casale CEO, Replacing Co-founder Richard Lowenthal
Reuters  ·  07-08
ARS Pharma Names President Donn Casale CEO, Replacing Co-founder Richard Lowenthal
ARS Pharmaceuticals - Richard Lowenthal to Step Down as CEO
THOMSON REUTERS  ·  07-08
ARS Pharmaceuticals - Richard Lowenthal to Step Down as CEO
ARS Pharmaceuticals - Appoints Donn Casale as CEO and Director
THOMSON REUTERS  ·  07-08
ARS Pharmaceuticals - Appoints Donn Casale as CEO and Director
Press Release: ARS Pharmaceuticals Announces CEO Succession
Dow Jones  ·  07-08
Press Release: ARS Pharmaceuticals Announces CEO Succession
ARS Pharma Shareholders Elect Directors at Annual Meeting
Reuters  ·  06-26
ARS Pharma Shareholders Elect Directors at Annual Meeting
ARS Pharmaceuticals Down over 24%, on Track for Largest Percent Decrease Since September 2023
Dow Jones  ·  06-26
ARS Pharmaceuticals Down over 24%, on Track for Largest Percent Decrease Since September 2023
ARS Pharmaceuticals is Maintained at Outperform by Leerink Partners
Dow Jones  ·  06-26
ARS Pharmaceuticals is Maintained at Outperform by Leerink Partners
ARS Pharma Tumbles as Allergy Nasal Spray Faces Insurance Coverage Hurdle
Reuters  ·  06-25
ARS Pharma Tumbles as Allergy Nasal Spray Faces Insurance Coverage Hurdle

Introduction

Company Name.
ARS PHARMACEUTICALS INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.
Issue price:
--